Skip to content
10-K

Annual Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-001019

← back to feed
Filed
Jun 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jun 1, 2026 207.03M sh
Cash And Equivalents FY 2025 · Jan 31, 2025 $0
Cash And Equivalents FY 2025 · Jan 31, 2024 $0
Shares Diluted FY 2025 · Jan 31, 2024 207.03M sh
Operating Cash Flow FY 2025 · Jan 31, 2024 −$34.92K
Current Liabilities FY 2025 · Jan 31, 2024 $3.49M
Total Liabilities FY 2025 · Jan 31, 2024 $3.49M
Current Assets FY 2025 · Jan 31, 2024 $23.63K
Total Assets FY 2025 · Jan 31, 2024 $137.34K
Eps Diluted FY 2025 · Jan 31, 2024 −$0.01
Sga Expense FY 2025 · Jan 31, 2024 $1.12M
Net Income FY 2025 · Jan 31, 2024 −$1.12M
Operating Income FY 2025 · Jan 31, 2024 −$1.12M
Revenue FY 2025 · Jan 31, 2024 $0
Stockholders Equity FY 2025 · Jan 31, 2023 −$2.4M